Anchyra Partners
CNTX icon

Anchyra Partners’s Context Therapeutics CNTX Stock Holding History

Anchyra Partners’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.13K Buy
+10,426
New +$5.14K ﹤0.01% 433

Other funds holding CNTX

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Landscape Capital Management
Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Anchyra Partners's CNTX Position: Q3 2026 in Review

Anchyra Partners opened a new position in Context Therapeutics (CNTX) in Q3 2026: 10,426 shares worth $3.13K. The stake represents ﹤0.01% of the portfolio and ranks #433 among its holdings.

38 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

  • Anchyra Partners held 10,426 shares of Context Therapeutics worth $3.13K as of Q3 2026.
  • Context Therapeutics was a new Anchyra Partners position in Q3 2026.
  • Context Therapeutics made up ﹤0.01% of Anchyra Partners's portfolio in Q3 2026, its #433 holding.
  • 38 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on Anchyra Partners's 13F filing for Q3 2026, filed 13 Oct 2026.